Oruka Therapeutics, Inc. — Director's Dealing 2021

Dec 16, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ARCA biopharma, Inc. (ABIO)
CIK: 0000907654
Period of Report: 2021-12-14

Reporting Person: BRISTOW MICHAEL R (Director, Pres. & Chief Executive Offic)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-12-14	Stock Option (right to buy)	$2.29	A	95000	Acquired	2031-12-14	Common Stock (95000)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	1109	Indirect
Common Stock	1414	Indirect
Common Stock	2285	Direct

Footnotes

F1: Grant to the Reporting Person of a stock option under the 2020 Equity Incentive Plan (the Plan), vesting in 36 equal monthly installments from the date of grant, provided that the Reporting Person's continuous service to the Issuer has not been terminated as defined in or as determined under the Plan prior to such time. In the event of a change in control of the Issuer, 50% of the unvested options shall become fully and immediately vested upon the closing date of such change in control, provided, however, that on the earlier of (i) the one-year anniversary of the closing date or (ii) involuntary termination, any options that remain unvested on such earlier date shall become fully and immediately vested.